RESULTS
PD‐L1, Cancer
ONCOLOGY, MALIGNANT TUMORS, CANCER
The baseline characteristics of patients in the nivolumab and placebo arms are presented in Table Baseline patient characteristics.Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; PD‐L1, programmed death‐ligand 1; TNM, the TNM classification of malignant tumors; UICC, Union for International Cancer Control.Interactive Web Response System source.Former smokers included anyone who had smoked even a small quantity of any tobacco and had stopped smoking at the time of screening. Current smokers are anyone who had a smoking habit of any tobacco regardless of smoking duration/quantity at the screening.There were five patients with indeterminate PD‐L1 expression levels in both arms.Overall survival with a minimum follow‐up period of 19.4 months (Kaplan–Meier plot). CI, confidence interval; HR, hazard ratio; OS, overall survival; mo, months.Subgroup analysis of overall survival. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; mo, months; NR, not reached; OS, overall survival; PD‐L1, programmed death‐ligand 1.Overall survival in patients stratified by programmed death‐ligand 1 expression level (Kaplan–Meier plots). There were five patients with indeterminate PD‐L1 expression levels in both arms. CI, confidence interval; HR, hazard ratio; mo, months; OS, overall survival; PD‐L1, programmed death‐ligand 1; NR, not reached.